AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

CAMBRIDGE, England--(BUSINESS WIRE/ AETOSWire )-- Today AstraZeneca revealed its
bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023.
This will be achieved through significant growth in its existing oncology, biopharmaceuticals
and rare disease portfolio, and by launching an expected 20 new medicines before the end of the
decade. To drive sustained growth beyond 2030, the Company will continue investing in
transformative new technologies and platforms that will shape the future of medicine.

AstraZeneca will maintain its strategic commitment to R&D while focusing on productivity
throughout the Company, driving operating leverage and enabling the delivery of its ambition for
a mid-30s percentage Core operating margin by 2026. Beyond 2026, Core operating margin will
be influenced by portfolio evolution and the company will target at least the mid-30s percentage
range.

Pascal Soriot, Chief Executive Officer, AstraZeneca said: “Today AstraZeneca announces a new
era of growth. In 2023 we delivered the ambitious $45 billion revenue goal set a decade ago.
With the exciting growth of our innovative pipeline, which has the potential to transform
millions of lives, we are now aiming for $80 billion by 2030.

We are planning to launch 20 new medicines by 2030, many with the potential to generate more
than $5 billion in peak year revenues. The breadth of our portfolio together with continued
investment in innovation supports sustained growth well past the end of the decade.”
As AstraZeneca continues to grow across all therapy areas, it will continue to decouple its carbon
emissions from its increase in revenue. The Company has already reduced its greenhouse gas
emissions (Scopes 1 and 2) by 68% from its 2015 baseline while growing Total Revenue by 85%
over the same period. By 2026 the Company will be carbon zero for Scope 1 and 2 emissions
and by 2030 halve its Scope 3 emissions, on the way to science-based net zero by 2045 at the
latest.